Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Development of the ICH guidelines for immunotoxicology evaluation of pharmaceuticals using a survey of industry practices.

Weaver JL, Tsutsui N, Hisada S, Vidal JM, Spanhaak S, Sawada J, Hastings KL, van der Laan JW, van Loveren H, Kawabata TT, Sims J, Durham SK, Fueki O, Matula TI, Kusunoki H, Ulrich P, Nakamura K.

J Immunotoxicol. 2005 Jul 1;2(3):171-80. doi: 10.1080/15476910500241339.

PMID:
18958670
2.

Lobucavir-induced proliferative changes in mice.

Woicke J, Durham SK, Mense MG.

Exp Toxicol Pathol. 2007 Nov;59(3-4):197-204. Epub 2007 Oct 17.

PMID:
17942294
3.

Hermaphroditism in a Sprague-Dawley rat.

Diters RW, Funk KA, Fang H, Durham SK, Mense MG.

Vet Pathol. 2007 May;44(3):418-20.

PMID:
17491092
4.

Atrioventricular valvular angiectasis in Sprague-Dawley rats.

Fang H, Howroyd PC, Fletcher AM, Diters RW, Woicke J, Sasseville VG, Bregman CL, Freebern WJ, Durham SK, Mense MG.

Vet Pathol. 2007 May;44(3):407-10.

PMID:
17491089
5.

Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: effects of moxifloxacin.

Holzgrefe HH, Cavero I, Buchanan LV, Gill MW, Durham SK.

J Pharmacol Toxicol Methods. 2007 May-Jun;55(3):227-37. Epub 2006 Sep 15.

PMID:
17097307
6.

Measurement of vitamin D status: background, clinical use, and methodologies.

Hart GR, Furniss JL, Laurie D, Durham SK.

Clin Lab. 2006;52(7-8):335-43. Review.

PMID:
16955631
7.

Novel probabilistic method for precisely correcting the QT interval for heart rate in telemetered dogs and cynomolgus monkeys.

Holzgrefe HH, Cavero I, Gleason CR, Warner WA, Buchanan LV, Gill MW, Burkett DE, Durham SK.

J Pharmacol Toxicol Methods. 2007 Mar-Apr;55(2):159-75. Epub 2006 May 27.

PMID:
16857392
8.

Distinct roles of NF-kappaB p50 in the regulation of acetaminophen-induced inflammatory mediator production and hepatotoxicity.

Dambach DM, Durham SK, Laskin JD, Laskin DL.

Toxicol Appl Pharmacol. 2006 Mar 1;211(2):157-65. Epub 2005 Aug 2.

PMID:
16081117
9.

Probabilistic neural network multiple classifier system for predicting the genotoxicity of quinolone and quinoline derivatives.

He L, Jurs PC, Kreatsoulas C, Custer LL, Durham SK, Pearl GM.

Chem Res Toxicol. 2005 Mar;18(3):428-40.

PMID:
15777083
10.
11.

Predicting the genotoxicity of polycyclic aromatic compounds from molecular structure with different classifiers.

He L, Jurs PC, Custer LL, Durham SK, Pearl GM.

Chem Res Toxicol. 2003 Dec;16(12):1567-80.

PMID:
14680371
12.

Role of tumor necrosis factor receptor 1 (p55) in hepatocyte proliferation during acetaminophen-induced toxicity in mice.

Chiu H, Gardner CR, Dambach DM, Durham SK, Brittingham JA, Laskin JD, Laskin DL.

Toxicol Appl Pharmacol. 2003 Dec 1;193(2):218-27.

PMID:
14644624
13.

Exaggerated hepatotoxicity of acetaminophen in mice lacking tumor necrosis factor receptor-1. Potential role of inflammatory mediators.

Gardner CR, Laskin JD, Dambach DM, Chiu H, Durham SK, Zhou P, Bruno M, Gerecke DR, Gordon MK, Laskin DL.

Toxicol Appl Pharmacol. 2003 Oct 15;192(2):119-30.

PMID:
14550746
14.

Role of p55 tumor necrosis factor receptor 1 in acetaminophen-induced antioxidant defense.

Chiu H, Gardner CR, Dambach DM, Brittingham JA, Durham SK, Laskin JD, Laskin DL.

Am J Physiol Gastrointest Liver Physiol. 2003 Nov;285(5):G959-66. Epub 2003 Jul 3.

15.

Predicting the genotoxicity of thiophene derivatives from molecular structure.

Mosier PD, Jurs PC, Custer LL, Durham SK, Pearl GM.

Chem Res Toxicol. 2003 Jun;16(6):721-32.

PMID:
12807355
16.

Predicting the genotoxicity of secondary and aromatic amines using data subsetting to generate a model ensemble.

Mattioni BE, Kauffman GW, Jurs PC, Custer LL, Durham SK, Pearl GM.

J Chem Inf Comput Sci. 2003 May-Jun;43(3):949-63.

PMID:
12767154
17.

Reduced hepatotoxicity of acetaminophen in mice lacking inducible nitric oxide synthase: potential role of tumor necrosis factor-alpha and interleukin-10.

Gardner CR, Laskin JD, Dambach DM, Sacco M, Durham SK, Bruno MK, Cohen SD, Gordon MK, Gerecke DR, Zhou P, Laskin DL.

Toxicol Appl Pharmacol. 2002 Oct 1;184(1):27-36.

PMID:
12392966
18.

Differential effects of insulin-like growth factor binding proteins-1, -2, -3, and -6 on cultured growth plate chondrocytes.

Kiepe D, Ulinski T, Powell DR, Durham SK, Mehls O, Tönshoff B.

Kidney Int. 2002 Nov;62(5):1591-600.

19.

Role of CCR2 in macrophage migration into the liver during acetaminophen-induced hepatotoxicity in the mouse.

Dambach DM, Watson LM, Gray KR, Durham SK, Laskin DL.

Hepatology. 2002 May;35(5):1093-103.

PMID:
11981759
20.

Integration of computational analysis as a sentinel tool in toxicological assessments.

Pearl GM, Livingston-Carr S, Durham SK.

Curr Top Med Chem. 2001 Sep;1(4):247-55. Review.

PMID:
11899110
21.

Role of three FKHR phosphorylation sites in insulin inhibition of FKHR action in hepatocytes.

Scheimann AO, Durham SK, Suwanichkul A, Snuggs MB, Powell DR.

Horm Metab Res. 2001 Nov;33(11):631-8.

PMID:
11733864
22.

Computational methods to predict drug safety liabilities.

Durham SK, Pearl GM.

Curr Opin Drug Discov Devel. 2001 Jan;4(1):110-5. Review.

PMID:
11727316
23.

Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.

Colonno RJ, Genovesi EV, Medina I, Lamb L, Durham SK, Huang ML, Corey L, Littlejohn M, Locarnini S, Tennant BC, Rose B, Clark JM.

J Infect Dis. 2001 Nov 15;184(10):1236-45. Epub 2001 Oct 29.

PMID:
11679911
24.

Overexpression of the acid-labile subunit of the IGF ternary complex in transgenic mice.

Silha JV, Gui Y, Modric T, Suwanichkul A, Durham SK, Powell DR, Murphy LJ.

Endocrinology. 2001 Oct;142(10):4305-13.

PMID:
11564688
25.

Phenotypic manifestations of insulin-like growth factor-binding protein-3 overexpression in transgenic mice.

Modric T, Silha JV, Shi Z, Gui Y, Suwanichkul A, Durham SK, Powell DR, Murphy LJ.

Endocrinology. 2001 May;142(5):1958-67.

PMID:
11316761
27.

Effect of chronic renal failure and growth hormone therapy on the insulin-like growth factors and their binding proteins.

Powell DR, Liu F, Baker BK, Hinzt RL, Kale A, Suwanichkul A, Durham SK.

Pediatr Nephrol. 2000 Jul;14(7):579-83. Review.

PMID:
10912522
28.

Conservation of a growth hormone-responsive promoter element in the human and mouse acid-labile subunit genes.

Suwanichkul A, Boisclair YR, Olney RC, Durham SK, Powell DR.

Endocrinology. 2000 Feb;141(2):833-8.

PMID:
10650966
29.

Increased severity of glomerulonephritis in C-C chemokine receptor 2 knockout mice.

Bird JE, Giancarli MR, Kurihara T, Kowala MC, Valentine MT, Gitlitz PH, Pandya DG, French MH, Durham SK.

Kidney Int. 2000 Jan;57(1):129-36.

30.

Insulin-like growth factor-binding protein-3 binds fibrinogen and fibrin.

Campbell PG, Durham SK, Hayes JD, Suwanichkul A, Powell DR.

J Biol Chem. 1999 Oct 15;274(42):30215-21.

31.

Conservation of an insulin response unit between mouse and human glucose-6-phosphatase catalytic subunit gene promoters: transcription factor FKHR binds the insulin response sequence.

Ayala JE, Streeper RS, Desgrosellier JS, Durham SK, Suwanichkul A, Svitek CA, Goldman JK, Barr FG, Powell DR, O'Brien RM.

Diabetes. 1999 Sep;48(9):1885-9.

PMID:
10480625
32.

FKHR binds the insulin response element in the insulin-like growth factor binding protein-1 promoter.

Durham SK, Suwanichkul A, Scheimann AO, Yee D, Jackson JG, Barr FG, Powell DR.

Endocrinology. 1999 Jul;140(7):3140-6.

PMID:
10385407
33.

Utilization of genetically altered animals in the pharmaceutical industry.

Rudmann DG, Durham SK.

Toxicol Pathol. 1999 Jan-Feb;27(1):111-4. Review.

PMID:
10367684
34.

The heparin binding domain of insulin-like growth factor binding protein (IGFBP)-3 increases susceptibility of IGFBP-3 to proteolysis.

Durham SK, Suwanichkul A, Hayes JD, Herington AC, Powell DR, Campbell PG.

Horm Metab Res. 1999 Feb-Mar;31(2-3):216-25.

PMID:
10226805
35.

Oncostatin M: development of a pleiotropic cytokine.

Loy JK, Davidson TJ, Berry KK, Macmaster JF, Danle B, Durham SK.

Toxicol Pathol. 1999 Mar-Apr;27(2):151-5. Review.

PMID:
10207978
36.
37.

Captopril prevents nephropathy in HIV-transgenic mice.

Bird JE, Durham SK, Giancarli MR, Gitlitz PH, Pandya DG, Dambach DM, Mozes MM, Kopp JB.

J Am Soc Nephrol. 1998 Aug;9(8):1441-7.

38.

Plasminogen binds the heparin-binding domain of insulin-like growth factor-binding protein-3.

Campbell PG, Durham SK, Suwanichkul A, Hayes JD, Powell DR.

Am J Physiol. 1998 Aug;275(2):E321-31. doi: 10.1152/ajpendo.1998.275.2.E321.

PMID:
9688635
39.

The insulin-like growth factor axis and growth in children with chronic renal failure: a report of the Southwest Pediatric Nephrology Study Group.

Powell DR, Durham SK, Liu F, Baker BK, Lee PD, Watkins SL, Campbell PG, Brewer ED, Hintz RL, Hogg RJ.

J Clin Endocrinol Metab. 1998 May;83(5):1654-61.

PMID:
9589673
40.

Nuclear factor (NF)-kappa B2 (p100/p52) is required for normal splenic microarchitecture and B cell-mediated immune responses.

Caamaño JH, Rizzo CA, Durham SK, Barton DS, Raventós-Suárez C, Snapper CM, Bravo R.

J Exp Med. 1998 Jan 19;187(2):185-96.

41.
42.

Hypoxia stimulates human preproendothelin-1 promoter activity in transgenic mice.

Aversa CR, Oparil S, Caro J, Li H, Sun SD, Chen YF, Swerdel MR, Monticello TM, Durham SK, Minchenko A, Lira SA, Webb ML.

Am J Physiol. 1997 Oct;273(4):L848-55. doi: 10.1152/ajplung.1997.273.4.L848.

PMID:
9357861
43.

Hepatic nuclear factor 3 and high mobility group I/Y proteins bind the insulin response element of the insulin-like growth factor-binding protein-1 promoter.

Allander SV, Durham SK, Scheimann AO, Wasserman RM, Suwanichkul A, Powell DR.

Endocrinology. 1997 Oct;138(10):4291-300.

PMID:
9322942
44.

Insulin-like growth factor-binding protein-6 levels are elevated in serum of children with chronic renal failure: a report of the Southwest Pediatric Nephrology Study Group.

Powell DR, Liu F, Baker BK, Hintz RL, Durham SK, Brewer ED, Frane JW, Tonshoff B, Mehls O, Wingen AM, Watkins SL, Hogg RJ, Lee PD.

J Clin Endocrinol Metab. 1997 Sep;82(9):2978-84.

PMID:
9284730
45.

Bioactivity of a 29-kilodalton insulin-like growth factor binding protein-3 fragment present in excess in chronic renal failure serum.

Durham SK, Mohan S, Liu F, Baker BK, Lee PD, Hintz RL, Conover CA, Powell DR.

Pediatr Res. 1997 Sep;42(3):335-41.

PMID:
9284274
46.

Thymus dysfunction and chronic inflammatory disease in gp39 transgenic mice.

Clegg CH, Rulffes JT, Haugen HS, Hoggatt IH, Aruffo A, Durham SK, Farr AG, Hollenbaugh D.

Int Immunol. 1997 Aug;9(8):1111-22.

PMID:
9263008
48.

Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.

Flint OP, Masters BA, Gregg RE, Durham SK.

Toxicol Appl Pharmacol. 1997 Jul;145(1):91-8.

PMID:
9221828
49.

Kinetics of insulin-like growth factor (IGF) and IGF-binding protein responses to a single dose of growth hormone.

Lee PD, Durham SK, Martinez V, Vasconez O, Powell DR, Guevara-Aguirre J.

J Clin Endocrinol Metab. 1997 Jul;82(7):2266-74.

PMID:
9215305
50.

Modulation of growth factors by growth hormone in children with chronic renal failure. The Southwest Pediatric Nephrology Study Group.

Powell DR, Liu F, Baker BK, Hintz RL, Lee PD, Durham SK, Brewer ED, Frane JW, Watkins SL, Hogg RJ.

Kidney Int. 1997 Jun;51(6):1970-9.

Supplemental Content

Loading ...
Support Center